- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
C2P Capital Advisory Group Trims AbbVie Stake
Investment firm reduces holdings in pharmaceutical giant by nearly 30%
Apr. 4, 2026 at 8:41am
Got story updates? Submit your updates here. ›
An extreme close-up of the intricate inner workings of the financial industry reflects the complex dynamics shaping investment decisions.North Chicago TodayC2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lowered its position in AbbVie Inc. (NYSE:ABBV) by 29.8% during the fourth quarter, according to a recent SEC filing. The firm now owns 20,322 shares of the pharmaceutical company's stock, down from 28,932 shares previously.
Why it matters
This filing provides insight into the investment strategies of C2P Capital Advisory Group, a prominent financial advisory firm. Reductions in major holdings can signal a shift in market outlook or portfolio rebalancing by institutional investors.
The details
According to the filing, C2P Capital Advisory Group sold 8,610 shares of AbbVie stock during the fourth quarter. The firm's total holdings in AbbVie are now valued at $4.6 million. Several other large investors have also modified their positions in AbbVie in recent quarters.
- The filing covers the fourth quarter of 2025.
- C2P Capital Advisory Group reduced its AbbVie stake during this period.
The players
C2P Capital Advisory Group LLC
A financial advisory firm that manages investments and provides wealth management services.
AbbVie Inc.
A global biopharmaceutical company that develops and commercializes therapies in immunology, oncology, neuroscience, and other therapeutic areas.
The takeaway
This filing highlights the ongoing shifts in institutional investment strategies as market conditions evolve. Monitoring changes in major holdings can provide valuable insights into the broader trends shaping the pharmaceutical and healthcare sectors.
